An ongoing dialogue on HIV/AIDS, infectious diseases,
November 30th, 2009
WHO HIV Treatment Guidelines Updated
This just in:
WHO is now recommending that ART be initiated at a higher CD4 threshold of 350 cells/mm3 for all HIV-positive patients, including pregnant women, regardless of symptoms.
Which makes eminent sense, of course. Because if starting HIV therapy might prolong survival in developed countries, why shouldn’t it do the same in the developing world?
In fact, when you consider the higher incidence of TB and invasive bacterial infections in such settings, it could easily be argued — and has been argued — that starting early would net greater survival gains in resource-poor settings than it would here.
Plus, there’s the CIPRAHT001 Study, which proves it.
But there’s more — the new WHO guidelines also urge that countries “phase out” the use of stavudine in favor of less-toxic NRTIs, and that women continue breastfeeding so long as they are also on ART.
Good news all around.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Variability in Consult Volume Is a Major Contributor to Trainee Stress — What’s the Solution?
- How to Figure Out the Length of Antibiotic Therapy
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- Being a Good Doctor — Why Are the Simple Things So Hard?
- Printed Medical Textbooks — Going, Going, but Not Quite Gone
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- Oral Gepotidacin: A Promising Antibiotic for Management of Uncomplicated Urinary Tract Infection
- Same Arm, Opposite Arm — For COVID-19 Vaccination, Does It Matter?
- Neonatal Outcomes After COVID-19 mRNA Vaccination During Pregnancy
- Is Lyme Disease More Common Now — Or Not?
- Echinocandins May Not Augment Immune Responses to Candida auris
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster